All In Biotech

Drug Trial Radar · NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,960 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,960

Planned (sponsor's estimate)

Start

Oct 18, 2023

Primary completion

Jan 2032

Study completion Jul 2034

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

Conditions

  • Breast Cancer

Interventions

  • Ovarian Function Suppression + Aromatase InhibitorDrug

    Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.

  • Adjuvant Chemotherapy + Ovarian Function SuppressionDrug

    Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive breast cancer-free survival (IBCFS)Time frame: Time from randomization for duration of trial, 11 years

Locations

1,276 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Active not recruiting

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Recruiting

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska · Suspended

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Recruiting

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Recruiting

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Recruiting

  • Anchorage Oncology Centre

    Anchorage, Alaska · Suspended

  • Katmai Oncology Group

    Anchorage, Alaska · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska · Recruiting

  • Kingman Regional Medical Center

    Kingman, Arizona · Recruiting

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas · Recruiting

  • Baptist Health Medical Center - Little Rock

    Little Rock, Arkansas · Recruiting

  • CARTI Cancer Center

    Little Rock, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Kaiser Permanente-Anaheim

    Anaheim, California · Recruiting

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California · Recruiting

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Recruiting

  • PCR Oncology

    Arroyo Grande, California · Recruiting

  • Sutter Auburn Faith Hospital

    Auburn, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California · Recruiting

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • Keck Medicine of USC Buena Park

    Buena Park, California · Recruiting

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Recruiting

  • Mills-Peninsula Medical Center

    Burlingame, California · Recruiting

  • Marshall Cancer Center

    Cameron Park, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California · Recruiting

  • Mercy Cancer Center - Carmichael

    Carmichael, California · Recruiting

  • Mercy San Juan Medical Center

    Carmichael, California · Recruiting

  • Eden Hospital Medical Center

    Castro Valley, California · Recruiting

  • Enloe Medical Center

    Chico, California · Recruiting

  • Enloe Cancer Center

    Chico, California · Recruiting

  • Sutter Davis Hospital

    Davis, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Active not recruiting

Showing 40 of 1,276 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.